Emergent secures anthrax vaccine extension with US CDC

By Gareth Macdonald contact

- Last updated on GMT


Related tags: U.s. securities and exchange commission, Us

Emergent BioSolutions has signed a $911m (€862m) follow-on contract to supply nearly 30 million doses of its anthrax vaccine to the US Government.

The contract – detailed in a US Securities and Exchange Commission (SEC) filing​ – will see Emergent’s subsidiary – Emergent Biodefense Operations Lansing LLC – make BioThrax (anthrax vaccine absorbed) for the Centers for Disease Control and Prevention (CDC).

The five year deal is designed to supply the US Strategic National Stockpile (SNS) with the initial batch of BioThrax due to be delivered early next year. The agreement builds on an existing​ supply deal that expired in September.


Emergent CEO Daniel Abdun-Nabi predicted the contract ealirer this year, telling investors “the CDC advised us that they anticipate continued procurement of BioThrax in the second and third quarters, although they had not specified the specific number of doses to be purchased.”

The firm also announced it has received a notice of intent from the Biomedical Advanced Research and Development Authority (BARDA) to procure approximately $100m of BioThrax, deliverable within the next two years.

BioThrax is the only vaccine licensed by the US FDA for the prevention of anthrax disease. Emergent makes the product at its Lansing, Michigan campus.

In May​, Emergent announced its intention to increase capacity at the facility – known as building 55 – to allow it to produce up to 25 million doses of the vaccine each year. 

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us


View more